Experts showcase next-gen biotech solutions to climate crisis
Industry experts have presented the latest biotech solutions for tackling climate change at the first INDUSTRIA BIOTEC conference, Europe’s new forum for the industrial biotech sector.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2171 entries already.
Entries by Thomas Gabrielczyk
Stalicla SA and Evgen Pharma plc ink $160.5m licensing deal for SFX-01
Precision neuroscience company Stalicla SA has licensed SFX-01 from Evgen Pharma plc in neurodevelopmental disorders and schizophrenia.
Knowledge-based contract services
To install a newly created Chief Scientific Officer position and to hire a biotech veteran is a signal sent by Rentschler Biopharma, celebrating 150 years.
Clinical Microbiomics A/S bags €10m financing
Danish microbiome specialist Clinical Microbiomics A/S has completed a €10m growth financing led by – Seventure Partners.
EU starts largest study on factors affecting mental health
The EU Commission has granted £8.4m for Youth-GEMS, the largest ever study to identify genetic and other risks affecting mental health in adolescence.
Standing Ovation wins Industria Biotec’s start-up pitch
French Standing Ovation has won the start-up pitch of Industria Biotec, held for the first time in Berlin. The event presents biotechnological solutions to save the climate.
Screening Platform
Single B cell screening is a powerful and efficient strategy for generating antigen-specific monoclonal antibodies (mAbs).
A spotlight on tomorrow’s CRO
The CRO industry is predicted to grow considerably over the next five years. Trials are becoming more complex, and technology is becoming increasingly interwoven with processes. The CRO of tomorrow must be tech smart, agile, and environmentally conscious to remain relevant. In this changing landscape, how does a CRO cut through the noise in 2022-30?
Araris Biotech closes $24m Series A financing round
Swiss ADC maker Araris Biotech AG has added a $24m financing round to its CHF15.2m (S17.8m) seed round in 2020 to expand its portfolio of proprietary antibody drug conjugates.
New Protein Fund I supports 17 alternative protein start-ups
With money from its $50m New Protein Fund, Big Idea Ventures funds in 17 pre-seed plant-based, cell-based and microbial food, ingredient and technology companies.